HPGC(SH:600664) Xin Lang Cai Jing·2025-11-18 02:53Core Viewpoint - Harbin Pharmaceutical Group Co., Ltd. (哈药股份) has experienced a decline in stock price and financial performance, with significant net outflows of capital and a decrease in both revenue and net profit year-on-year [1][2][3] Financial Performance - As of September 30, 2025, Harbin Pharmaceutical reported a revenue of 12.02 billion yuan, a year-on-year decrease of 1.92% [2] - The net profit attributable to shareholders was 329 million yuan, reflecting a significant year-on-year decline of 35.35% [2] - The company's stock price has dropped by 9.20% year-to-date, with a recent trading price of 3.75 yuan per share [1] Stock Market Activity - On November 18, 2025, the stock price fell by 2.09%, with a trading volume of 116 million yuan and a turnover rate of 1.21% [1] - The company has seen a net outflow of 14.28 million yuan in principal funds, with large orders showing a buy of 24.06 million yuan and a sell of 29.60 million yuan [1] - Harbin Pharmaceutical has appeared on the stock market's "龙虎榜" three times this year, with the latest occurrence on January 13 [1] Shareholder Information - As of September 30, 2025, the number of shareholders increased to 98,100, with an average of 25,665 circulating shares per person, a decrease of 1.08% [2] - The top ten circulating shareholders include Hong Kong Central Clearing Limited, which reduced its holdings by 18.56 million shares [3] Dividend History - Since its A-share listing, Harbin Pharmaceutical has distributed a total of 7.3 billion yuan in dividends, but there have been no dividends paid in the last three years [3]